Last reviewed · How we verify
TRS005
At a glance
| Generic name | TRS005 |
|---|---|
| Sponsor | Zhejiang Teruisi Pharmaceutical Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL. (PHASE2)
- A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL (PHASE1, PHASE2)
- A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRS005 CI brief — competitive landscape report
- TRS005 updates RSS · CI watch RSS
- Zhejiang Teruisi Pharmaceutical Inc. portfolio CI